Editors' picks from other sources

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Drug interactions and pharmacokinetics news

Show

From To
Ageing and HIV
Top five concerns people with HIV have about ageing: Scotland

Through the Positive Persons' Forum and other initiatives, many people with HIV in Scotland have made it clear that they are very concerned about growing older with HIV. We have set out some of these concerns in the infographic below (or view it as a plain online image). The top 5 concerns were confidentiality, the effects of HIV medication, drug interactions, Financial stability and ignorance and stigma.

Published
12 August 2015
From
HIV Scotland-
Drug interactions and pharmacokinetics
'Lab on a card' can spot poor quality drugs

The tool is known as a PAD (Paper Analytical Device) and is essentially a mini lab on a piece of card, Mercy explains. "It's simple, you apply the tablet on a specific area on the device, dip the card in water and wait for a colour reaction, then compare the results to a standard to interpret the results." Each of the cards contains 12 separate strips which react with a drug to create a "coloured bar code" that gives information about its chemical content.

Published
08 June 2015
From
BBC Health
Drug interactions and pharmacokinetics
Almost Three Quarters of HIV/HCV Group May Have DDA-ARV Interactions

Among 125 HIV/HCV-coinfected people taking antiretrovirals in a Denver group, 70% could have moderate or severe interactions with one of four common direct-acting antiviral (DAA) regimens for HCV.

Published
02 June 2015
From
NATAP
Drug interactions and pharmacokinetics
Isentress (raltegravir) label update

On February 18, 2015, FDA approved changes to the Isentress (raltegravir) label to include updated information regarding the coadministration of raltegravir and aluminum and/or magnesium containing antacid.

Published
19 February 2015
From
FDA
HIV treatment
Viral Load Reductions Persist With Less Efavirenz for HIV

The virologic responses with reduced-dose efavirenz at 48 weeks have proven durable out to 96 weeks, ENCORE1 study results show.

Published
07 November 2014
From
Medscape (requires free registration)
PEP
Change to recommended regimen for post-exposure prophylaxis (PEP)

The Expert Advisory Group on AIDS (EAGA) has recommended a change in the recommended regimen for post-exposure prophylaxis from tenofovir/emtricitabine with Kaletra to tenofovir/emtricitabine with raltegravir.

Published
11 September 2014
From
Expert Advisory Group on AIDS (EAGA)
Drug interactions and pharmacokinetics
Dosage of HIV drug may be ineffective for half of African-Americans

Many African-Americans may not be getting effective doses of the HIV drug maraviroc. The initial dosing studies included mostly European-Americans, who generally lack a protein that is key to removing maraviroc from the body, resulting in higher concentrations of the drug in the blood. The current study shows that people with maximum levels of the protein CYP3A5 -- including nearly half of African-Americans -- end up with lower levels of maraviroc in their bodies.

Published
28 August 2014
From
Eurekalert Medicine & Health
Hepatitis C treatment
Opioid Therapy No Bar to Novel HCV Drugs

People on opioid substitution therapy for drug addiction can be safely and effectively treated for hepatitis C (HCV) with an investigational combination of medications, researchers said here.

Published
24 July 2014
From
MedPage Today
Cancer
Advice on Best ART Regimen for Patients Taking Cancer Therapy

Because no clinical trials address the question and published data are insufficient to support guidelines, the optimal antiretroviral therapy (ART) regimen for patients undergoing cancer chemotherapy remains unknown. But experts from Houston’s M.D. Anderson Cancer Center offer suggestions to help clinicians individualize therapy for each patient.

Published
25 June 2014
From
International AIDS Society
TB treatment
In HIV/TB coinfection, raltegravir may be an alternative to efavirenz

Patients coinfected with HIV and tuberculosis (TB) may benefit from raltegravir as an alternative to efavirenz, new research suggests.

Published
02 June 2014
From
Medscape
← Prev1...23456...9Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.